Antigenics fails to regain Nasdaq compliance
This article was originally published in Scrip
Executive Summary
Antigenicshas failed to regain compliance with the Nasdaq's marketplace rule that requires a minimum market value of $50 million in listed securities. The company received a delisting warning at the end of November and had until December 22nd to regain compliance with the rule (Scrip Online, November 28th, 2008). Antigenics now intends to request a hearing with the Nasdaq Listing Qualifications Panel to present its plan to maintain its listing. The company's shares will continue to be listed pending the panel's decision following the hearing.